Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
23757 | 281 | 41.0 | 91% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
157 | 21931 | BENIGN PROSTATIC HYPERPLASIA//PROSTATE CANCER//PROSTATE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | EBP1 | Author keyword | 42 | 83% | 9% | 24 |
2 | RADIOBIOL CANC | Address | 4 | 75% | 1% | 3 |
3 | PA2G4 | Author keyword | 2 | 67% | 1% | 2 |
4 | AUTOCRINE GROWTH REGULATION | Author keyword | 2 | 43% | 1% | 3 |
5 | ERBB3 BINDING PROTEIN 1 | Author keyword | 1 | 100% | 1% | 2 |
6 | M1B PROSTATE CANCER | Author keyword | 1 | 100% | 1% | 2 |
7 | CLIN PHARMACOL NEW DRUGS DEV UNIT | Address | 1 | 25% | 1% | 3 |
8 | ANDROGEN INDEPENDENT TUMORS | Author keyword | 1 | 50% | 0% | 1 |
9 | APOPTOTIC CLEAVAGE | Author keyword | 1 | 50% | 0% | 1 |
10 | CANC MOL IMAGING UNIT | Address | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | EBP1 | 42 | 83% | 9% | 24 | Search EBP1 | Search EBP1 |
2 | PA2G4 | 2 | 67% | 1% | 2 | Search PA2G4 | Search PA2G4 |
3 | AUTOCRINE GROWTH REGULATION | 2 | 43% | 1% | 3 | Search AUTOCRINE+GROWTH+REGULATION | Search AUTOCRINE+GROWTH+REGULATION |
4 | ERBB3 BINDING PROTEIN 1 | 1 | 100% | 1% | 2 | Search ERBB3+BINDING+PROTEIN+1 | Search ERBB3+BINDING+PROTEIN+1 |
5 | M1B PROSTATE CANCER | 1 | 100% | 1% | 2 | Search M1B+PROSTATE+CANCER | Search M1B+PROSTATE+CANCER |
6 | ANDROGEN INDEPENDENT TUMORS | 1 | 50% | 0% | 1 | Search ANDROGEN+INDEPENDENT+TUMORS | Search ANDROGEN+INDEPENDENT+TUMORS |
7 | APOPTOTIC CLEAVAGE | 1 | 50% | 0% | 1 | Search APOPTOTIC+CLEAVAGE | Search APOPTOTIC+CLEAVAGE |
8 | EPIDERMIAL GROWTH FACTOR RECEPTOR | 1 | 50% | 0% | 1 | Search EPIDERMIAL+GROWTH+FACTOR+RECEPTOR | Search EPIDERMIAL+GROWTH+FACTOR+RECEPTOR |
9 | HER 2 NEU PROTEIN | 1 | 50% | 0% | 1 | Search HER+2+NEU+PROTEIN | Search HER+2+NEU+PROTEIN |
10 | HERCEPTEST TM | 1 | 50% | 0% | 1 | Search HERCEPTEST+TM | Search HERCEPTEST+TM |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ERBB 3 BINDING PROTEIN | 17 | 70% | 5% | 14 |
2 | ANDROGEN INDEPENDENCE | 8 | 19% | 13% | 36 |
3 | BINDING PROTEIN EBP1 | 6 | 48% | 4% | 10 |
4 | ERB B 2 NEU PROTOONCOGENE | 6 | 71% | 2% | 5 |
5 | P38 2G4 | 6 | 100% | 1% | 4 |
6 | ERBB3 BINDING PROTEIN | 4 | 67% | 1% | 4 |
7 | EBP1 | 3 | 40% | 2% | 6 |
8 | PROTEIN EBP1 | 3 | 60% | 1% | 3 |
9 | HER 2 NEU ONCOPROTEIN | 2 | 27% | 3% | 8 |
10 | ERBB 3 | 2 | 33% | 1% | 4 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Profiling serum HER-2/NEU in prostate cancer | 2013 | 3 | 47 | 49% |
Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond | 2011 | 9 | 54 | 31% |
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer | 2001 | 30 | 26 | 35% |
Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu) | 2010 | 8 | 34 | 18% |
Her-2/neu receptor in prostate cancer development and progression to androgen independence | 2004 | 23 | 79 | 22% |
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer | 2012 | 10 | 130 | 8% |
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies | 2006 | 99 | 215 | 5% |
Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro | 2006 | 15 | 79 | 13% |
Kinase Inhibitors in Prostate Cancer | 2009 | 1 | 134 | 10% |
Smart drugs in prostate cancer | 2004 | 27 | 166 | 7% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RADIOBIOL CANC | 4 | 75% | 1.1% | 3 |
2 | CLIN PHARMACOL NEW DRUGS DEV UNIT | 1 | 25% | 1.1% | 3 |
3 | CANC MOL IMAGING UNIT | 1 | 50% | 0.4% | 1 |
4 | CHAIR UROL CLIN | 1 | 50% | 0.4% | 1 |
5 | LIFE SCI BIO PHARMACEUT | 1 | 50% | 0.4% | 1 |
6 | SANTO ANDRE | 1 | 50% | 0.4% | 1 |
7 | STATE OTOLARYNGOL HEAD NECK SURG | 1 | 50% | 0.4% | 1 |
8 | UNIV SURG CANC SCI MOL PATHOL | 1 | 50% | 0.4% | 1 |
9 | HUMAN COMPARAT PROSTATE CANC GENOM | 0 | 33% | 0.4% | 1 |
10 | JUNG STILLING HOSP | 0 | 33% | 0.4% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000192028 | HER3//NUCLEAR EGFR//EGFR FAMILY |
2 | 0.0000151250 | ANDROGEN RECEPTOR//ANDROGEN INSENSITIVITY SYNDROME//ANDROGEN INSENSITIVITY |
3 | 0.0000139865 | LZTS1//UROGENE//NUCLEAR ROUNDNESS |
4 | 0.0000137156 | C ERBB 2//HER 2 NEU//P185 |
5 | 0.0000135534 | ABIRATERONE//ENZALUTAMIDE//CASTRATION RESISTANT PROSTATE CANCER |
6 | 0.0000117231 | NIMOTUZUMAB//H R3//CETUXIMAB |
7 | 0.0000108865 | PROSTATE DEVELOPMENT//BIOL SCI VET MED//PROSTATE STEM CELL |
8 | 0.0000108151 | UNIT IMMUNOMICROBIO ENVIRONM CARCINOGENESIS//ANTI INTERLEUKIN 6 ANTIBODY//AUTOCRINE AND PARACRINE LOOPS |
9 | 0.0000069128 | CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS |
10 | 0.0000066003 | AGR2//C44A//LYPD3 |